



**In Search of a Goldilocks Reference Case
in the US:**

**Could an Insured Member or Patient-
Informed Reference Case Be 'Just Right?'**



ICER's Reference Case for Economic Evaluations: Principles and Rationale

Current as of January 31, 2020

Appendix A. Impact Inventory (adapted from Neumann, Sanders et al.⁶)

Note that the purpose of this checklist is to report whether different impacts were considered in the health system payer and modified societal perspective analyses. Not all impact types will be relevant for every intervention. For example, some interventions may have impacts limited to the formal healthcare sector, while other interventions may have substantial impacts beyond the formal healthcare sector.

Sector	Type of Impact (Add additional domains, as relevant)	Included in This Analysis from... Perspective?		Notes on Sources (if quantified), Likely Magnitude & Impact (if not)
		Health Care Sector	Societal	
Formal Health Care Sector				
Health outcomes	Longevity effects	☐	☐	
	Health-related quality of life effects	☐	☐	
	Adverse events	☐	☐	
Medical costs	Paid by third-party payers	☐	☐	
	Paid by patients out-of-pocket	☐	☐	
	Future related medical costs	☐	☐	
	Future unrelated medical costs	☐	☐	
Informal Health Care Sector				
Health-related costs	Patient time costs	NA	☐	
	Unpaid caregiver-time costs	NA	☐	
	Transportation costs	NA	☐	
Non-Health Care Sectors				
Productivity	Labor market earnings lost	NA	☐	
	Cost of unpaid lost productivity due to illness	NA	☐	
	Cost of uncompensated household production	NA	☐	
Consumption	Future consumption unrelated to health	NA	☐	
Social services	Cost of social services as part of intervention	NA	☐	
Legal/Criminal justice	Number of crimes related to intervention	NA	☐	
	Cost of crimes related to intervention	NA	☐	
Education	Impact of intervention on educational achievement of population	NA	☐	
Housing	Cost of home improvements, remediation	NA	☐	
Environment	Production of toxic waste pollution by intervention	NA	☐	
Other	Other impacts (if relevant)	NA	☐	


NA: not applicable

Goal: evidence-based fair price for newly launched patented medical intervention

Acknowledge that health care has gotten so expensive that it is beyond the reach of many Americans (including those with health insurance)

Desire to reward companies when they can demonstrate that therapies address patient priorities and unmet needs

Results of an HTA can positively or negatively impact patients access to care



Adopting either reference case could result in *higher or lower* fair price estimates... more information does not necessarily mean a higher price



Jon Campbell, PhD

Senior Vice President
Institute for Clinical and
Economic Review



**Elisabeth Oehrlein,
PhD, MS**

Founder & Principal
Scientist
Applied Patient
Experience, LLC



Julia F. Slejko, PhD

Associate Professor
University of Maryland
School of Pharmacy

